Pharmacodynamics of selective inhibition of γ-secretase by avagacestat

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 3, 2013, Pages 686-695

  Albright, Charles F ^a   Dockens, Randy C ^a   Meredith, Jere E ^a   Olson, Richard E ^a   Slemmon, Randy ^a   Lentz, Kimberley A ^a   Wang, Jun Sheng ^a   Denton, R Rex ^a   Pilcher, Gary ^a   Rhyne, Paul W ^a   Raybon, Joseph J ^a   Barten, Donna M ^a   Burton, Catherine ^a   Toyn, Jeremy H ^a   Sankaranarayanan, Sethu ^a   Polson, Craig ^a   Guss, Valerie ^a   White, Randy ^a   Simutis, Frank ^a   Sanderson, Thomas ^a   Gillman, Kevin W ^a   Starrett, John E ^a   Bronson, Joanne ^a   Sverdlov, Oleksandr ^a   Huang, Shu Pang ^a   Castaneda, Lorna ^a   Feldman, Howard ^a   Coric, Vlad ^a   Zaczek, Robert ^a   Macor, John E ^a   Houston, John ^a   Berman, Robert M ^a   Tong, Gary ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOG; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; GOBLET CELL METAPLASIA; HUMAN; HUMAN EXPERIMENT; INTESTINE METAPLASIA; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPLENIC MARGINAL ZONE LYMPHOMA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELLS, CULTURED; DOGS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SULFONAMIDES; YOUNG ADULT;

EID: 84874426209     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199356     Document Type: Article

References (53)

1. Ang HL and Tergaonkar V (2007) Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function? Bioessays 29: 1039-1047.
2. Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, and Robertson BJ, et al. (2005) Dynamics of beta-amyloid reductions in brain, cerebrospinal fluid, and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J Pharmacol Exp Ther 312: 635-643.
3. Barten DM, Meredith JE, Jr, Zaczek R, Houston JG, and Albright CF (2006) Gammasecretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity. Drugs R D 7:87-97.
4. Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, Barbour R, Bova M, Chen XH, and Dappen MS, et al. (2010) Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther 2:36-57.
5. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, and May PC, et al. (2009) A gammasecretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66:48-54.
6. Bergmans BA and De Strooper B (2010) gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurol 9:215-226.
7. Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, and Boussiquet-Leroux C, et al. (2007) The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320:552-558.
8. Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, and Thompson MW, et al. (2008) The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 283:22992-23003.
9. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, and Esselmann H, et al. (2012) The mechanism of g-Secretase dysfunction in familial Alzheimer disease. EMBO J 31: 2261-2274.
10. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, and Sonnenberg-Reines J, et al. (2005) Acute gammasecretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25:8898-8902.
11. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, and Pilcher G, et al. (2012) Safety and tolerability of the g-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol1-12 .
12. Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS, Bales KR, Johnson DS, and Li Y-M (2012) BMS-708,163 targets presenilin and lacks notchsparing activity. Biochemistry 51:7209-7211.
13. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
14. Desai AK, Grossberg GT, and Sheth DN (2004) Activities of daily living in patients with dementia: Clinical relevance, methods of assessment and effects of treatment. CNS Drugs 18:853-875.
15. Dockens R, Wang JS, Castaneda L, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, and Berman RM, et al. (2012) A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet 51:681-693.
16. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, and Quinn JF, et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038.
17. Gillman KW, Starrett JE, Jr, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, and Williams R, et al. (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med Chem Lett 1:120-124.
18. Gnanadesikan R and Kettenring JR (1972) Robust estimates, residuals, and outlier detection with multiresponse data. Biometrics 28:81-124.
19. Gu H, Deng Y, Wang J, Aubry AF, and Arnold ME (2010) Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci 878:2319-2326.
20. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
21. Henley DB, May PC, Dean RA, and Siemers ER (2009) Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 10:1657-1664.
22. Hyde LA, McHugh NA, Chen J, Zhang Q, Manfra D, Nomeir AA, Josien H, Bara T, Clader JW, and Zhang L, et al. (2006) Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5- difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther 319: 1133-1143.
23. Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, and Pilotto A (2011) Therapeutic intervention for Alzheimer's disease with g-secretase inhibitors: Still a viable option? Expert Opin Investig Drugs 20:325-341.
24. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, and Maloney J, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99.
25. Kopan R and Ilagan MX (2009) The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137:216-233.
26. Kreft A, Harrison B, Aschmies S, Atchison K, Casebier D, Cole DC, Diamantidis G, Ellingboe J, Hauze D, and Hu Y, et al. (2008) Discovery of a novel series of Notchsparing g-secretase inhibitors. Bioorg Med Chem Lett 18:4232-4236.
27. Kumano K, Masuda S, Sata M, Saito T, Lee SY, Sakata-Yanagimoto M, Tomita T, Iwatsubo T, Natsugari H, and Kurokawa M, et al. (2008) Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. Pigment Cell Melanoma Res 21:70-78.
28. Lewis HD, Pérez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, and Shearman MS (2003) Catalytic site-directed g-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and b-APP cleavages. Biochemistry 42:7580-7586.
29. Li T, Wen H, Brayton C, Das P, Smithson LA, Fauq A, Fan X, Crain BJ, Price DL, and Golde TE, et al. (2007a) Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J Biol Chem 282: 32264-32273.
30. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, and Price DL, et al. (2007b) Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27: 10849-10859.
31. Mahalanobis PC (1936) On the generalised distance in statistics. Proc Nat Inst Sci India 12:49-55.
32. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, and Harrison B, et al. (2009) Begacestat (GSI-953): A novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 331:598-608.
33. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, and Ciaccio PJ (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82: 341-358.
34. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, and Matsuoka N (2012) Differential effects between g-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32:2037-2050.
35. Olson RE and Albright CF (2008) Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem 8:17-33.
36. Pollack SJ and Lewis H (2005) Secretase inhibitors for Alzheimer's disease: Challenges of a promiscuous protease. Curr Opin Investig Drugs 6:35-47.
37. Prasad CV, Zheng M, Vig S, Bergstrom C, Smith DW, Gao Q, Yeola S, Polson CT, Corsa JA, and Guss VL, et al. (2007) Discovery of (S)-2-((S)-2-(3,5- difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4, 5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): A gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. Bioorg Med Chem Lett 17:4006-4011.
38. Querfurth HW and LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362: 329-344.
39. Radtke F, Wilson A, Mancini SJ, and MacDonald HR (2004) Notch regulation of lymphocyte development and function. Nat Immunol 5:247-253.
40. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, and Radtke F (2008) Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 9:377-383.
41. Ross JS and Imbimbo BP (2010) Are g-secretase inhibitors detrimental for Alzheimer's disease patients? J Alzheimers Dis 22:401-404.
42. Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K, Yamaguchi T, Yamamoto G, Seo S, and Kumano K, et al. (2003) Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 18:675-685.
43. Selkoe DJ (2007) Developing preventive therapies for chronic diseases: Lessons learned from Alzheimer's disease. Nutr Rev 65:S239-S243.
44. Sharma A and Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24:611-635.
45. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, and Knopman DS, et al. (2006) Effects of a gammasecretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66:602-604.
46. Steiner H, Fluhrer R, and Haass C (2008) Intramembrane proteolysis by g-secretase. J Biol Chem 283:29627-29631.
47. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, and Li H, et al. (2012a) Multicenter, randomized, double-blind, placebocontrolled, single-ascending dose study of the oral g-secretase inhibitor BMS-708163 (Avagacestat): Tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 34:654-667.
48. Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, and Berman RM, et al. (2012b) Effects on single doses of avagacestat (BMS-708163) on cerebrospinal fluid Ab levels in healthy young men. Clin Drug Investig 32:761-769.
49. Walsh DM and Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
50. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, and Lee HJ, et al. (2004) Chronic treatment with the gammasecretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882.
51. Wu WL and Zhang L (2009) Gamma-secretase inhibitors for the treatment of Alzheimer's disease. Drug Dev Res 70:94-100.
52. Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, and Zheng H (2001) Loss of presenilin 1 is associated with enhanced b-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci USA 98:10863-10868.
53. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, and Xu H (2007) Presenilin/g-secretasedependent processing of b-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 104:10613-10618.